EXACT Sciences Corporation (EXAS) Eyes Sale of Another $200 Million in Stock  
3/6/2013 9:04:18 AM

Exact Sciences has filed a shelf registration that will let the company sell up to another $200 million worth of stock to the public over the next three years. The Madison company, which is developing a non-invasive, stool-based test for colorectal cancer, has no plans to sell any of the shares in the near future, chief executive Kevin Conroy said.